[ The <font color="blue">chemotherapy_1</font> <font color="blue">of_1</font> <font color="blue">advanced_3</font> <font color="blue">breast_3</font> <font color="blue">cancer_3</font> <font color="blue">._3</font> A report on the <font color="blue">first_1</font> <font color="blue">600_3</font> <font color="blue">cases_3</font> <font color="blue">in_2</font> <font color="blue">a_2</font> <font color="blue">cooperative_2</font> <font color="blue">programme_2</font> <font color="blue">to_2</font> <font color="blue">carry_2</font> <font color="blue">out_2</font> <font color="blue">a_2</font> <font color="blue">systematic_2</font> <font color="blue">study_2</font> <font color="blue">(_1</font> <font color="blue">1974_1</font> <font color="blue">-_1</font> <font color="blue">1977_1</font> <font color="blue">)_1</font> ( author 's transl ) ] . 
<br>
<br> The authors explain the objectives and the structure of a programme evolved for the <font color="blue">methodic_1</font> <font color="blue">study_1</font> <font color="blue">of_1</font> <font color="blue">advanced_2</font> <font color="blue">breast_2</font> <font color="blue">cancers_2</font> which they have worked out and carried out in cooperation with the <font color="blue">departments_3</font> <font color="blue">of_3</font> <font color="blue">medicine_3</font> <font color="blue">in_3</font> <font color="blue">eight_3</font> <font color="blue">French_3</font> <font color="blue">anticancer_3</font> <font color="blue">centres_3</font> <font color="blue">._3</font> They analyse the initial phases , which correspond to the three first years of work . They give the state of the results that have been obtained in <font color="blue">603_5</font> <font color="blue">patients_5</font> using three protocols for treatment . These consisted of the administration in <font color="blue">interrupted_1</font> <font color="blue">doses_1</font> <font color="blue">of_1</font> <font color="blue">chemotherapy_1</font> <font color="blue">which_1</font> <font color="blue">consisted_1</font> <font color="blue">of_1</font> <font color="blue">vincristine_1</font> <font color="blue">associated_1</font> <font color="blue">for_1</font> <font color="blue">the_1</font> <font color="blue">one_1</font> <font color="blue">part_1</font> <font color="blue">with_1</font> <font color="blue">cyclophosphamide_1</font> <font color="blue">and_1</font> <font color="blue">5-fluoro_1</font> <font color="blue">-_1</font> <font color="blue">uracil_1</font> <font color="blue">and_1</font> <font color="blue">on_1</font> <font color="blue">the_1</font> <font color="blue">other_1</font> <font color="blue">hand_1</font> <font color="blue">with_1</font> <font color="blue">doxorubicine_1</font> <font color="blue">or_1</font> <font color="blue">/_1</font> <font color="blue">and_1</font> <font color="blue">with_1</font> <font color="blue">methotrexate_1</font> <font color="blue">._1</font> From this study there emerged the value of combined therapy using doxorubicine as much because of the frequency with which results better than 50% were obtained ( in a randomised trial ) as by their quality , which was made clear in an important <font color="blue">series_2</font> <font color="blue">of_2</font> <font color="blue">240_2</font> <font color="blue">cases_2</font> <font color="blue">._2</font> They point out the conditions required to initiate the place of such a scheme in all complex therapy which aims as much at palliation as at cure , and point out how important it is to be methodical in the application of chemotherapy in order to ensure its development as an anticancer therapy .